SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

DK-Crush in Left Main Bifurcations: Rewiring Selection According to Bifurcation Angle

Dr. Omar Tupayachi - 14 May, 2026 0

Complex coronary bifurcation PCI, especially in the left main coronary artery (LMCA), represents one of the most technically demanding scenarios in interventional cardiology. Among...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Dr. Juan Manuel Pérez - 14 May, 2026 0

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

Left Atrial Appendage Closure: Implantation Depth Could Determine Thrombosis Risk

Dr. Andrés Rodríguez - 12 May, 2026 0

Left atrial appendage closure (LAAC) has undergone significant advances over the past two decades. This progress has been driven by the development of new...

Noticias Institucionales

SOLACI granted its scientific endorsement to CITIC 2026

solaci - 13 May, 2026 0

The Latin American Society of Interventional Cardiology (SOLACI) has granted its scientific endorsement to CITIC 2026, one of the region’s leading academic and technological...

A Look Back at Panamá Sessions 2026

solaci - 12 May, 2026 0

Scientific updates, hands-on workshops, and strong regional participation in Panama City The LIV SOLACI Panamá 2026 Sessions brought together interventional cardiology specialists, fellows, technicians, and...

See the Best Moments From 2026 Panamá Sessions

solaci - 12 May, 2026 0

Relive the most memorable moments of the 2026 Panamá Sessions, held on May 8 and 9, 2026, at the Megapolis Hotel in Panama City. Two...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad

Tag: thrombosis

Bioresorbable Scaffolds Must Not Be Chosen Over Current DES

These Are the Thrombosis Predictors for Absorb Bioresorbable Scaffolds

Dual antiplatelet therapy discontinuation causes more thrombotic events at 12 months

Risk of Thrombosis and Bleeding with Peripheral Artery Disease and Concomitants

SOLACI CACI 2017 | Prevention of valvular thrombosis: antiaggregation or anticoagulation?

Incidence, characteristics, and treatment of valve thrombosis after TAVR

AIDA: bioresorbable scaffold thrombosis still a concern in studies

Post TAVR thrombosis, is it more common than we know?

Bioresorbable scaffolds with drug-eluting stents: do they entail a higher thrombosis...

Very Late Thrombosis: Bioresorbable Scaffolds vs. Everolimus-Eluting Metallic Drug-Eluting Stents